Is it safe?
Can MLTX take a bad year?
MoonLake Immunotherapeutics holds $259M more cash than debt, and is burning $56M a quarter, about 1.6 years of cover.
$259M
Net cash
- Net debt / EBITDA
- net cash
Net debt / EBITDA · no net borrowings to measure against earnings
- Cash runway
- 1.6 years
Cash runway · burning $56M a quarter at the current rate
- Annualised volatility
- 91%
Annualised volatility · three times the market's own swing
Details›
- Total debtQ1 2026
- $99M
- Cash and short-term investments
- $358M
- Net cash
- $259M
- EBITDA, trailing twelve months
- −$264M
- Operating profit, trailing twelve months
- −$267M
- Debt / equity
- 0.39×
- Annualised volatilitytwo years of daily moves
- 91%
- Worst drawdown on file
- −90%
- Below its 52-week high
- −75%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.